Gan and Lee Pharmaceuticals, USA
29
4
5
20
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
3.4%
1 terminated/withdrawn out of 29 trials
95.2%
+8.7% vs industry average
10%
3 trials in Phase 3/4
10%
2 of 20 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (29)
Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State
Role: lead
A Study of GZR18 Injection in Obese/Overweight Patients
Role: lead
Comparison Study of Insulin GZR4 With Insulin Degludec
Role: lead
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Role: lead
A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus
Role: lead
A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM
Role: lead
Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment
Role: lead
A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects
Role: lead
A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD
Role: lead
A Study to Evaluate the Safety, Tolerance, PK and PD Parameters of GZR33 and GZR101 in Healthy Male Adult Subjects
Role: lead
A Clinical Study of GZR33 and GZR101 in Healthy Subjects
Role: lead
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes
Role: lead
A Study of GZR18 Tablet in Chinese Healthy Subjects
Role: lead
A Phase I Study of GZR18 Injection in Obese/Overweight Subjects
Role: lead
A Phase I Study of GZR18 Injection in Healthy Subjects
Role: lead
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4
Role: lead
A Study of GZR4 Injection at Different Injection Sites
Role: lead
Gan & Lee Insulin Glargine Target Type (1) Evaluating Research
Role: lead
A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
Role: lead
A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)
Role: lead